Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response
- Status
- RECRUITING
- Phase
- N/A
Clinical Trials Related to Sacituzumab govitecan
Related studies linked through entity extraction aliases.
Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
- Status
- RECRUITING
- Phase
- PHASE2
Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC)
- Status
- RECRUITING
- Phase
- PHASE2
Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas
- Status
- TERMINATED
- Phase
- PHASE2
Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Sacituzumab Govitecan Combined With Head Radiotherapy for Her2-negative Breast Cancer Brain Metastases
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.
- Status
- RECRUITING
- Phase
- PHASE3
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Real-world Effectiveness and Safety Study of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer
- Status
- RECRUITING
- Phase
- N/A